The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Greg Harrison from Bank of America. Maybe start off with one for Dr. Weiner. What other agents do you think would be promising to combine with
701 instead of or in addition to pembrolizumab?
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Okay. Great. That's helpful. And then maybe one for the company. In the Phase IIb, what do you think is the appropriate bar for response rate if
you were to assume pembro monotherapy would give ORR in single digits or close to 0? Is 20% for the combo the right way to think about what
the target should be?
Vincent J. O'Neill - BioXcel Therapeutics, Inc. - Senior VP and Chief Research & Development Officer of OnkosXcel Therapeutics
This is, just to clarify, small cell neuroendocrine we're talking, right?
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: So I know that recently in the second-line small cell lung cancer setting, Zepzelca was approved. Just maybe any overall thoughts on that product
as it relates to the specific patient population? And then my second question, as you look to explore higher doses, is it just the cytokine release
that you're most worried about? Or is there another element of the potential toxicity profile that we should be looking out for?
Vincent J. O'Neill - BioXcel Therapeutics, Inc. - Senior VP and Chief Research & Development Officer of OnkosXcel Therapeutics
So I think given the fact that we are in the IST that we've just described, we are going to give the drug for just 3 days every day. And the -- again,
this is empirical so we have to test it. But the expectation is with a short duration, we can get those peaks without the cytokine phenomenon
coming back. They tend to occur on a standard days 1 to 14 therapeutic schedule usually at the end of the first week. So I'm hopeful we're going
to be able to just avoid seeing that.
What was dose-limiting for Point Therapeutics was peripheral edema, right? Will that come back? Again, because of the pulse nature, I don't -- I'm
not -- again, I don't know, but the expectation is, no, we really will -- should anyway avoid seeing those adverse events come back. And then your
first question, I've forgotten already.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
FEBRUARY 21, 2023 / 6:00PM, BTAI.OQ - BioXcel Therapeutics Inc To Host BXCL701 Key Opinion Leader Day
|
